Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SRZN · against 596 other Healthcare companies listed in US-listed
Ranked #362 of 597 · scores higher than 39% of peers · safety percentile 31
Bars: peers in each 10-point band of the safety percentile (higher = safer; 67+ earns the lower-risk grade)54 peers with a safety percentile of 30–39, including SRZN · Click a bar to see the companies
Mainly because of its debt / equity, which is weaker than most Healthcare peers.
Risk is relative to the sector, not a bankruptcy probability. Banks and brokers carry high leverage by design, and share buybacks can shrink equity and current assets, which raises debt/equity on paper.
| Metric | SRZN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Debt / equityLower is better · 523 reported | Not reported | 0.23× | — | — | 33% |
| BetaLower is better · 556 reported | 0.56 | 0.95 | 73% | 33% | |
| Current ratioHigher is better · 600 reported | 12.14× | 3.91× | 83% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Safety | Overall |
|---|---|---|---|---|
| 1 | 5.6B USD | 100 | 53 | |
| 1 | 6.6B USD | 100 | 45 | |
| 3 | 186M USD | 100 | 52 | |
| 4 | 1.5B USD | 100 | 44 | |
| 5 | 1.2B USD | 100 | 40 | |
| 358 | 1.3B USD | 31 | 20 | |
| 359 | 302.7B USD | 31 | 63 | |
| 360 | 1.6B USD | 31 | 30 | |
| 361 | 1.2B USD | 31 | ||
| 362 | 354M USD | 31 | 13 | |
| 363 | 38.4B USD | 31 | 50 | |
| 364 | 119.1B USD | 30 | 57 | |
| 365 | 45.2B USD | 30 | 46 | |
| 366 | 787M USD | 30 | 57 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score